GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Cyclically Adjusted PB Ratio

Fortress Biotech (FRA:CNB1) Cyclically Adjusted PB Ratio : (As of May. 28, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Fortress Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Fortress Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Cyclically Adjusted PB Ratio Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.12 2.11 0.55 0.20

Fortress Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.48 0.27 0.20 0.14

Competitive Comparison of Fortress Biotech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Fortress Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Cyclically Adjusted PB Ratio falls into.



Fortress Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Fortress Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Fortress Biotech's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.37/131.7762*131.7762
=2.370

Current CPI (Mar. 2024) = 131.7762.

Fortress Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201406 18.030 100.560 23.627
201409 18.193 100.428 23.872
201412 18.452 99.070 24.544
201503 17.807 99.621 23.555
201506 15.947 100.684 20.872
201509 15.202 100.392 19.954
201512 16.603 99.792 21.924
201603 12.373 100.470 16.228
201606 9.693 101.688 12.561
201609 10.016 101.861 12.958
201612 11.187 101.863 14.472
201703 13.308 102.862 17.049
201706 19.119 103.349 24.378
201709 9.191 104.136 11.631
201712 13.068 104.011 16.556
201803 9.617 105.290 12.036
201806 10.449 106.317 12.951
201809 8.642 106.507 10.692
201812 0.422 105.998 0.525
201903 4.377 107.251 5.378
201906 6.210 108.070 7.572
201909 4.995 108.329 6.076
201912 4.781 108.420 5.811
202003 6.431 108.902 7.782
202006 9.354 108.767 11.333
202009 13.191 109.815 15.829
202012 13.039 109.897 15.635
202103 13.719 111.754 16.177
202106 13.827 114.631 15.895
202109 11.967 115.734 13.626
202112 14.222 117.630 15.932
202203 12.535 121.301 13.617
202206 10.172 125.017 10.722
202209 8.630 125.227 9.081
202212 5.346 125.222 5.626
202303 4.060 127.348 4.201
202306 1.946 128.729 1.992
202309 1.748 129.860 1.774
202312 2.313 129.419 2.355
202403 2.370 131.776 2.370

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fortress Biotech  (FRA:CNB1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Fortress Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines